What is Longevity Biotech?
Longevity Biotech is a biopharmaceutical company focused on developing precise disease-modifying therapies to improve the quality of life for individuals suffering from neurodegenerative diseases. Leveraging innovative scientific approaches such as immune rebalancing and precision neuroscience, the company aims to tackle complex neurological conditions. Their pipeline includes active clinical trials, notably for Parkinson's disease, demonstrating a clear dedication to pioneering advanced treatment modalities for patients and the broader medical community.
How much funding has Longevity Biotech raised?
Longevity Biotech has raised a total of $60K across 1 funding round:
Debt
$60K
Debt (2021): $60K with participation from PPP
What's next for Longevity Biotech?
With the recent influx of expansion capital, Longevity Biotech is poised for significant growth and pipeline acceleration. This funding is expected to fuel the progression of their clinical trials, potentially leading to breakthroughs in treating neurodegenerative disorders like Parkinson's disease. The company's strategic focus on immune rebalancing and precision neuroscience positions it to capture a substantial share of the market for advanced neurological therapies, reinforcing its trajectory within the significant Series B/C stage of its corporate lifecycle.
See full Longevity Biotech company page
